OR WAIT null SECS
Medidata, a global provider of creating end-to-end solutions to support the entire clinical trial process, and a Dassault Systèmes company, announced that Medpace Inc. has entered into an agreement to integrate Medidata Rave Imaging with Medpace's imaging systems and workflow. This will create a platform for capturing, managing, analyzing and storing images and imaging data for clinical trials. Medpace is a contract research organization (CRO) with a wholly owned and fully integrated imaging core lab that offers a suite of global imaging services to enhance and expedite biopharmaceutical and medical device development.
Glen de Vries, co-founder and co-CEO of Medidata, said, “As drug and medical device development depend more on medical imaging, it’s more important than ever to simplify and unify image and data collection. This helps to minimize risk and complexity, and ensures accurate, rapid completion of clinical studies so patients can more quickly benefit from new therapeutics.”
The use and importance of medical imaging in clinical studies continues to grow. Today, over 50 percent of all studies use medical imaging to help determine the efficacy of new drugs and devices and 95 percent when it is an oncology study. Medidata Rave Imaging is an end-to-end cloud-based platform for image management in clinical trials. This includes image capture, advanced edit checks, workflow, form design, electronic data capture (EDC) connection, and intelligent archiving. Medidata processes more than 500 million images annually from nearly 800 studies.
Using Medidata Rave Imaging, Medpace’s imaging core lab will:
“Through our partnership with Medidata, Medpace is now able to provide integration of our quantitative image analysis pipelines with Medidata’s Rave Imaging system and database,” said Daniel O’Leary, MD, chief medical officer for Medpace’s imaging core lab.